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ABSTRACT
Chemotherapy is considered “state of the art” for the treatment of poorly differentiated neuroendocrine neoplasms. 
Unfortunately, there is no standard effective post-first-line treatment for relapsing high-grade gastroenteropancreatic 
neuroendocrine neoplasms. We report the case of a patient with a gastric neuroendocrine carcinoma stage IV, with 
massive gastrointestinal bleeding at diagnosis. After the first line of platin-based chemotherapy a major tumoral response 
was documented, but the patient relapsed after 4 months. A second line of chemotherapy treatment was given, with 
the FOLFOX regimen, and the patient has been free of progression for almost 2 years. There is no second-line standard 
treatment accepted for this type of carcinoma, but 5-fluorouracil combined with oxaliplatin showed interesting antitumor 
activity. 
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INTRODUCTION
Neuroendocrine neoplasms (NENs), which arise 
from the gastroenteropancreatic (GEP) system, 
define a group of heterogeneous diseases with a 
growing incidence.1,2 According to histopathological 
characteristics, NENs can be classified in neuroendocrine 
tumors (NETs) and neuroendocrine carcinomas (NECs). 
NECs usually show more aggressive behavior, and 
patients are usually diagnosed with metastatic 
disease.2,3 The European guidelines recommends that 
systemic chemotherapy should be the treatment of 
choice for metastatic poorly differentiated NECs.2,4 
We present the case of a poorly differentiated gastric 
neuroendocrine carcinoma that had a sustained major 
response to a second line of chemotherapy with 
5-fluorouracil (5-FU) combined with oxaliplatin.
CASE REPORT
A 63-year-old male with no previous significant 
medical history was admitted to our department after 
hemorrhagic shock. He complained of dysphagia and 
asthenia for 2 weeks followed by abdominal pain and 
melena over the past 3 days. On physical examination, 
he presented with pale skin, blood pressure of 
99/69 mmHg and tachycardia of 110 bpm. There were 
no palpable masses on the abdomen. The laboratory 
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tests showed a hemoglobin level of 6.8 g/dL (reference 
value [RV]: 14-17.5 g/dL), a hematocrit of 20.5% 
(RV: 40-54%), and a normal platelet count. The liver 
function tests, renal function tests, and coagulation 
results were normal. The electrocardiogram, and the 
chest and abdominal x-rays showed no abnormal 
findings. A gastroesophageal transit and an upper 
abdominal endoscopy were performed; an important 
ulcerated tumor was seen, which involved the 
esophagogastric junction and the gastric fundus with 
active bleeding (Figure 1A).
A computed tomography (CT) scan (Figure 1B) 
was also performed and revealed extensive gastric 
wall thickening extending from the cardia through the 
minor curvature. Large masses in the gastrohepatic 
ligament and celiac trunk were also described, which 
were consistent with a conglomerate of lymph 
nodes. The size of the primary tumor was around 
10.6 × 7.8 × 8.4 cm, and the left gastric artery was 
invaded. The CT also showed several enlarged lymph 
nodes in the retroperitoneum, a 20 mm mass in 
segment VII of the liver, nodules of 16 mm and 10 mm 
in the right adrenal gland, and 12 mm in the left 
adrenal gland, which were consistent with metastases.
The gastric tumor was biopsied. Microscopic 
examination showed malignant epithelial proliferation 
forming nests of large cells, with no glandular 
differentiation. Immunohistochemistry disclosed diffuse 
cytokeratin AE1/AE3 and diffuse synaptophisin staining, 
focal chromogranin positivity and Ki-67 proliferation 
index of 90%. Histopathological diagnosis was gastric 
carcinoma with neuroendocrine differentiation, grade 3.
(Figure 2). As the biopsy was taken by endoscopy, 
the mitotic index could not be established in 
10 high-power fields (HPF). However, in an isolated 
HPF, four mitotic figures were found.
The extended laboratory blood work-up showed an 
elevated chromogranin A of 586 ng/mL (RV: <36.4 ng/mL) 
and enolase of 94.8 ng/mL (RV: ≤15 ng/mL).
The clinical staging was cT4N1M1, stage IV, 
according to the tumor, node, and metastasis 
(TNM) classification for gastric endocrine tumors 
(European Neuroendocrine Tumor Society).5-7 
The case was presented at the hospital multidisciplinary 
tumor board and systemic treatment was initiated 
with carboplatin (AUC5, at day 1) and etoposide 
(100 mg/m2 at days 1, 2, and 3). The patient was 
discharged after the first cycle of chemotherapy; he 
was clinically steady, tolerating oral diet and without 
any signs of bleeding.
After the end of six cycles of chemotherapy, a 
control CT scan (Figures 3A and 3B) revealed a partial 
tumoral response, with almost complete recovery of 
the gastric wall; however, a lymph node of 20 mm 
remained in the celiac axis.
On the fourth month of follow-up, a new CT scan 
(Figure 4A) showed a 70 mm mass in the gastrohepatic 
ligament.
Figure 1. A – Gastroesophageal transit showing a huge mass involving the esophagogastric junction and the gastric 
fundus; B – CT scan showing an exophytic mass in the lesser gastric curvature referring to the known gastric cancer 
(asterisk).
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Figure 2. Photomicrography of the gastric biopsy. A – Nests of a poorly differentiated carcinoma stained with 
hematoxylin-eosin; B – Diffuse cytoplasmic synaptophysin immunostaining; C – High cell proliferation index, showing 
90% of Ki-67 positive cells.
Figure 3. A and B – CT-scans revealing a major tumoral response, with almost complete recovery of the gastric wall 
(black arrow), but a lymph node of 20 mm remained in the celiac axis (white arrow).
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The patient started second-line treatment with 
mFOLFOX6 (oxaliplatin 85 mg/m2; folinic acid 
200 mg/m2; 5-FU 400 mg/m2; and an infusion of 
2 400 mg/m2 for 46 hours), every 14 days. Tree months 
after, on re-evaluation of the first CT scan, there was 
a partial tumoral response. The patient presented with 
grade 3 neuropathy, which lead to the discontinuation 
of oxaliplatin on the 16th cycle, while the CT scans 
showed a sustained partial response, and continued 
with the De Gramont scheme ((folinic acid 200 mg/m2; 
5-FU 400 mg/m2; and an infusion of 2 400 mg/m2 
for 46 hours, every 14 days). The patient has been 
free of tumor progression for 24 months, on the 44th 
cycle of the De Gramont scheme and the last CT scan 
(Figure 4B) documented a sustained major tumoral 
response.
The patient signed an informed consent and the 
case report is in accordance with the institution’s ethics 
committee.
DISCUSSION
The classification for GEP NENs was recently 
revised. The World Health Organization defines 
grade 3 GEP carcinomas according to a Ki-67 greater 
than 20% and/or mitosis greater than 20/HPF. 
The recommended therapeutic regimen for grade 
3 neuroendocrine tumors is the systemic chemotherapy 
with platinum plus etoposide.2,4,8 Grade 3 carcinomas 
show diverse responses and outcomes to chemotherapy. 
Some studies have shown a correlation between Ki-67 
and the response to a platinum-based chemotherapy, 
while others have shown longer survival rates with 
lower Ki-67 values.9-11 A new sub-classification, which 
was recently proposed by Fazio and Milione,12 uses the 
term “tumor” for morphological well-differentiated 
neoplasms, and “carcinoma” for poorly differentiated 
neoplasms, and classified GEP NENs according to 
the Ki67 index. In this setting, they suggest using an 
alkylating-based or oxaliplatin-based chemotherapy 
for poorly differentiated GEP NET G3, with a Ki-67 
inferior to 55%, while the poorly-differentiated GEP 
NECs with a Ki-67 superior to 55% should be treated 
with cisplatin/carboplatin plus etoposide.12
Treatment  wi th  f i r s t - l ine  chemotherapy 
usually results in response rates around 42%; the 
median duration of response is approximately 
9.2 months.11 However, our patient responded 
well to the platin-etoposide chemotherapeutic 
regimen, but relapsed within 4 months. There is no 
standard second-line therapy established for GEP 
tumors. The European Society for Medical Oncology 
guidelines refer to promising results regarding a 
fluoropyrimidine drug associated with oxaliplatin or 
irinotecan.2 The response rate with irinotecan is known 
to be around 31%, with disease stabilization also 
around 31%, and a median progression free survival 
(PFS) of 4 months.13 Alternatively, Hadoux et al.14 
evaluated the antitumor activity of 5-FU and oxaliplatin 
(FOLFOX) chemotherapy in poorly differentiated 
Figure 4. A – CT scan showing local relapse (asterisk); B – The sustained major tumoral response after the 44th cycle 
of chemotherapy (arrow).
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grade 3 neuroendocrine carcinomas that relapsed 
after the cisplatin-based regimen. This French 
retrospective study revised 17 patients—all with distant 
metastases—in which 11 patients (64%) had a stable 
disease/partial response with FOLFOX; the median 
PFS was 4.5 months. An Italian Group15 also analyzed 
the response to the oxaliplatin-based scheme (n = 78) 
and documented a PFS of 8 months. After receiving 
16 cycles (approximately 8 months) of FOLFOX, our 
patient is still on the De Gramont scheme with good 
tolerability, showing a PFS (until now) superior to the 
aforementioned studies.
The activity of other chemotherapy regimens 
has been evaluated only in small retrospective studies 
for poorly differentiated tumors. Welin et al.16 
tested temozolomide alone or in combination with 
bevacizumab and capecitabine, in patients who had a 
platinum failure, achieving a median overall survival of 
22 months. Other approaches, such as monotherapy 
docetaxel, or FOLFIRI, showed similar results.13,17
CONCLUSION
The prognosis for grade 3 NECs is dismal.6,10 
Evidence on what should be the second line of 
chemotherapy is still lacking. Our patient presents 
an excellent response to the FOLFOX regimen as a 
second line of chemotherapy; nevertheless, further 
larger, prospective studies and guidelines are needed 
to establish an optimal second-line treatment.
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